Evidence map›Paper›PMID 40017248›Full record

ReviewCurrent drug targets2025

Targets Involved in the Pharmacology of Bothrops Snakebite:

Alisson Emannuel Franco Alves, Allessya Lara Dantas Formiga, Ana Flavia Chaves Uchoa, Anny Leticia Marinho Ramos Cardoso, Eduardo Oliveira Aquino Leal Rodrigues, Graziela Maria de Araujo Pereira, Julia de Padua Farias Bezerra Leite, Luis Fellipe Alves da Silva, Natalia Ferreira de Sousa, Marcelo da Silva Sobral and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alisson Emannuel Franco AlvesDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.ORCID 0000-0001-7590-7107
Allessya Lara Dantas FormigaDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.ORCID 0000-0001-6632-9851
Ana Flavia Chaves UchoaDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.ORCID 0000-0001-6872-082X
Anny Leticia Marinho Ramos CardosoDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.
Eduardo Oliveira Aquino Leal RodriguesDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.
Graziela Maria de Araujo PereiraDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.
Julia de Padua Farias Bezerra LeiteDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.
Luis Fellipe Alves da SilvaDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.ORCID 0000-0001-7179-7043
Natalia Ferreira de SousaPost-graduated Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.ORCID 0000-0001-7131-6414
Marcelo da Silva SobralPost-graduated Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.
Marcus Tullius ScottiPost-graduated Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.
Luciana ScottiPost-graduated Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.
Francisco Humberto Xavier JuniorDepartament of Pharmacy, Laboratory of Pharmaceutical Biotechnology (BioTecFarm), Federal University of Paraiba (UFPB), Campus I- Castelo Branco III. 58051-900, João Pessoa-PB, Brazil.ORCID 0000-0001-8238-3380

Funding

Paraíba State Research Foundation [FAPESQ] 1866/2022
6 · The paper itself

Abstract

Despite their hazardous nature, snake venoms hold immense potential for the development of novel therapies. This summary delves into the key aspects of snake venom research, focusing on their significance as targets for neutralization, their utility as novel drugs, the application of in silico studies, and future prospects with nanotechnology. Significance of Snake Venom: Snake venom harbors a rich diversity of toxic proteins with a wide range of biological activities. Its importance lies in the possibility of neutralizing its detrimental effects and exploring its therapeutic potential for diverse ailments. Venom Neutralization: The development of more effective and specific antivenoms is crucial for treating snakebites, particularly in regions with a high prevalence of accidents. Molecular-level venom studies are essential for identifying novel targets for the development of more efficacious antivenoms. Venom as a Source of Novel Drugs: Proteins present in snake venom exhibit diverse pharmacological activities, including antithrombotic, anti-inflammatory, analgesic, and antimicrobial properties. Investigating these proteins can lead to the development of novel medications for various diseases. In silico Studies: Bioinformatics tools and molecular modelling can aid in the discovery of novel molecular targets in snake venom, accelerating the process of developing new drugs and therapies. Nanotechnology for Drug Delivery: Nanotechnology offers new possibilities for developing more efficient and targeted drug delivery systems, enhancing the safety and effectiveness of snake venom- based treatments. Snake venom research represents a promising area of inquiry with immense potential for the development of novel drugs and therapies. The integration of traditional and innovative techniques, such as

Indexed as

AntiveninsBothropsCrotalid VenomsSnake BitesAnimalsComputational BiologyDrug Delivery SystemsHumansNanotechnologySnake VenomsAntiveninsCrotalid VenomsSnake Venomsbioprospectingdrug delivery.drug developmentin silico studiesnanotechnologySnake venom

Identifiers

PMID40017248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.